Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.23126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a Deep Learning Denoising Algorithm for Dose Reduction in Whole-Body Photon-Counting CT Imaging: A Cadaveric Study.
Acad Radiol
January 2025
Department of Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany (R.D., J.M.B., B.S., J.M., S.G., P.K., S.W., J.H., K.N., S.A., A.B.).
Rationale And Objectives: Photon Counting CT (PCCT) offers advanced imaging capabilities with potential for substantial radiation dose reduction; however, achieving this without compromising image quality remains a challenge due to increased noise at lower doses. This study aims to evaluate the effectiveness of a deep learning (DL)-based denoising algorithm in maintaining diagnostic image quality in whole-body PCCT imaging at reduced radiation levels, using real intraindividual cadaveric scans.
Materials And Methods: Twenty-four cadaveric human bodies underwent whole-body CT scans on a PCCT scanner (NAEOTOM Alpha, Siemens Healthineers) at four different dose levels (100%, 50%, 25%, and 10% mAs).
Validation of clearcalc for efficient patient specific QA.
Med Dosim
January 2025
Medical Technology, Health Information and Research Directorate, Ministry of Health, Jerusalem, Israel.
Uganda's only radiotherapy center is a very busy facility treating about 210 patients daily on three linear accelerators making it sometimes hard to have machine time for pretreatment QAs. This study was aimed at validating an independent calculation software, ClearCalc (ICS) for second checks of the treatment planning system (TPS) calculations. The validation of ICS started with simple phantom test plans consisting of square, irregular, open and wedged fields designed in the TPS and measured in phantoms.
View Article and Find Full Text PDFDevelopment of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.
Urol Oncol
January 2025
Vita-Salute San Raffaele University and IRCCS San Raffaele Hospital, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele University, Milan, Italy.
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFEmerging biomarkers in Gaucher disease.
Adv Clin Chem
January 2025
Center for Orphan Drug Research, Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, United States. Electronic address:
Gaucher disease (GD) is a rare lysosomal disorder characterized by the accumulation of glycosphingolipids in macrophages resulting from glucocerebrosidase (GCase) deficiency. The accumulation of toxic substrates, which causes the hallmark symptoms of GD, is dependent on the extent of enzyme dysfunction. Accordingly, three distinct subtypes have been recognized, with type 1 GD (GD1) as the common and milder form, while types 2 (GD2) and 3 (GD3) are categorized as neuronopathic and severe.
View Article and Find Full Text PDFPlasma D-Dimer Changes and Clinical Value in Acute Lower Extremity Deep Venous Thrombosis Treated with Catheter-Directed Thrombolysis.
J Vasc Surg Venous Lymphat Disord
January 2025
Department of Vascular Surgery, Chenzhou First People's Hospital and the First Affiliated, Hospital of Xiangnan University, Chenzhou, Hunan Province 423000, China. Electronic address:
Objective: This study sought to investigate the changes in plasma D-dimer levels during catheter-directed thrombolysis (CDT) in patients with acute lower extremity deep venous thrombosis (DVT), analyze imaging results, and assess their clinical implications.
Methods: We retrospectively analyzed 62 patients diagnosed with acute lower extremity DVT who underwent CDT between March 2019 and December 2022. Plasma D-dimer levels were measured before CDT, at regular intervals after CDT, and at the end of CDT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!